You searched for "Diabetic macular oedema"
Pathophysiology of diabetic macular oedema: why combination therapy may be better
1 October 2015
| Winfried MK Amoaku
|
EYE - Vitreo-Retinal
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)
3 April 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...
OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
1 December 2021
| Su Young
|
EYE - Vitreo-Retinal
|
Diabetic macular edema, aflibercept, optical coherence tomography, predictive, ranibizumab
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....
Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema
1 October 2015
| Bheemanagouda Patil
|
EYE - Vitreo-Retinal
Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...
Ranibizumab versus laser in diabetic macular oedema (LUCIDATE study)
1 October 2014
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
The aim of this study was to compare the functional and structural effects of Ranibizumab versus macular laser treatment in patients with diabetic macular oedema. It was a single centre, prospective, randomised, single masked clinical trial spanning a 48 week...
Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders
3 February 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Aflibercept, Anti-VEGF, Dexamethasone implant, Diabetic macular oedema, Persistent, Ranibizumab, Resistant
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...